Completed PHASE1 INTERVENTIONAL 1-arm NCT03419910

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

An Open-Label, Single-Sequence Study to Investigate the Effects of Cyclosporine on the Pharmacokinetics of BMS-986165 at Steady State in Healthy Male Participants

Sponsor: Bristol-Myers Squibb

Conditions Psoriasis

Interventions BMS-986165 Cyclosporine

Updated 8 times since 2018 Last updated: Mar 17, 2020 Started: Mar 5, 2018 Primary completion: May 4, 2018 Completion: May 4, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Psoriasis and is currently completed. Bristol-Myers Squibb leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2020 — Jan 2021 [monthly]

Completed PHASE1
Aug 2018 — Apr 2020 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Mar 2018 — Apr 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salt Lake City, United States